New drug combination effective for patients with advanced ovarian cancer

Ad Details

  • Ad ID: 7113

  • Added: February 14, 2022

  • Views: 22

Description

A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.

Comments

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments